Stimulation of anti-melanoma immune effectors via modified tumour cells exhibiting inhibited IGF-I and low CD9.
Modified melanoma cells (B16-F0.MOD) characterized by inhibited IGF-I, CD9 low but not their wild-type counterparts (B16-F0.WT), IGF-I positive, CD9 high, were shown to be immunogenic for syngeneic hosts. C57BL/6 syngeneic recipients vaccinated with B16-F0.MOD cells developed immune effectors that were observed at the humoral as well as cellular levels. These immune effectors were shown to be capable of controlling in vitro tumour growth and in vivo tumour progression.
Trabado
Séverine
S
Laboratoire de Toxicologie, Faculté de Pharmacie, Université René Descartes Paris 5, Paris, France.
Van Binh
Pascale Nguyen
PN
Martin
Chantal
C
Lafarge-Frayssinet
Christiane
C
Lone
Yu-Chun
YC
Trojan
Jerzy
J
Warnet
Jean-Michel
JM
Duc
Huynh-Thien
HT
D000818:Animals; D000917:Antibody Formation; D015703:Antigens, CD / Q000096:biosynthesis*; D045744:Cell Line, Tumor; D002470:Cell Survival; D005434:Flow Cytometry; D007111:Immunity, Cellular; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis*; D008546:Melanoma, Experimental / Q000276:immunology* / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D014611:Vaccination
D015703:Antigens, CD; D007334:Insulin-Like Growth Factor I